Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348985 · ClinicalTrials.gov registry record · Phase 1
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00348985: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00348985 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00348985, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with bortezomib may kill more cancer cells.
Interventions
- OTHER pharmacological study
- DRUG bortezomib
- DRUG belinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348985
The ClinicalTrials.gov registry entry for NCT00348985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00348985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348985 about?
NCT00348985 is a clinical study titled "PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas". This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to...
What is the current status of trial NCT00348985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00348985?
The interventions under investigation include: pharmacological study (OTHER), bortezomib (DRUG), belinostat (DRUG).
Who is sponsoring clinical trial NCT00348985?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.